Experts discuss how to manage fatigue, abdominal pain, and other treatment-related symptoms to maintain or improve quality of life for patients undergoing HER2-targeted therapy and share strategies ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements.

The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive ...

With the demonstration of the ability to measure HER2 circulating tumour cells status dynamically over time, Angle said it successfully completed its contract with Eisai. Separately, Angle said ...

Patients and Methods: A total of 320 patients with AOC were centrally screened for HER2 status (243 patients in fi rst line, 77 in relapse). All positive (IHC 3+) and doubtful (IHC 2+) cases were ...

In addition to determining the hormone receptor and HER2 protein status, healthcare teams use the TNM system to identify the stages. This system notes: Your oncologist will use scoring of these ...

(“CSPC”) (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Breakthrough Therapy Designation by the Center for Drug Evaluation ...

Now, those patients with low HER2 status might be eligible for targeted treatment and a significant potential improvement in outcome, as they will be considered for the specifically engineered ...

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

For the study, investigators pitted the HER2-targeted antibody-drug conjugate ... The latest trial win won’t affect Enhertu’s regulatory status in the U.S. Back in 2021, the FDA approved ...

Abstract: Accurate assessment of Human Epidermal growth factor receptor 2 (HER2) status in breast cancer is crucial for determining treatment eligibility for targeted therapies. Although machine ...